Drug Trial Radar · NCT01818752
Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma
Last checked: Nov 20, 2026Latest source record: Aug 26, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
955
Actual
Start
Jul 8, 2013
Primary completion
Jul 15, 2016
Study completion Nov 4, 2016
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Mar 26, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective was to compare the progression-free survival of transplant ineligible patients newly diagnosed with multiple myeloma who were treated with carfilzomib, melphalan and prednisone (CMP) or with Velcade® (bortezomib), melphalan and prednisone (VMP).
Conditions
- Multiple Myeloma
Interventions
CarfilzomibDrug
Carfilzomib was administered over 30 minutes on days 1, 2, 8, 9, 22, 23, 29, and 30 for nine 42-day cycles. Carfilzomib 20 mg/m² IV was administered on days 1 and 2 of cycle 1, followed by escalation to 36 mg/m² IV starting on day 8 of cycle 1.
BortezomibDrug
Bortezomib 1.3 mg/m² was administered as a bolus IV injection or as a subcutaneous injection (per investigator's choice, dose modification, or regulatory approval) on days 1, 4, 8, 11, 22, 25, 29, and 32 of cycles 1 to 4, and on days 1, 8, 22, and 29 of cycles 5 to 9.
MelphalanDrug
Melphalan 9 mg/m² was taken orally on days 1 to 4 of all cycles.
PrednisoneDrug
Prednisone 60 mg/m² was taken orally on days 1 to 4 of all cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS)Time frame: From randomization until the data cut-off date of 15 July 2016; median follow-up time for PFS was 21.6.and 22.2 months in the bortezomib and carfilzomib arms respectively.
Locations
213 sites in 30 countries. Site status is shown where the registry gives one.
California Cancer Associates for Research & Excellence, Inc. (cCARE)
Fresno, California
Marin Cancer Care
Greenbrae, California
Sutter Gould Medical Foundation
Modesto, California
Innovative Clinical Research Institute
Whittier, California
UF Health Shands Cancer Hospital
Gainesville, Florida
Evanston KelIogg Cancer Center
Evanston, Illinois
Billings Clinic Cancer Center
Billings, Montana
Maimonides Cancer Center
Brooklyn, New York
Weill Cornell Medical Center
New York, New York
Gabrail Cancer Center Research
Canton, Ohio
Saint Francis Health System
Greenville, South Carolina
Spartanburg Regional Healthcare System
Spartanburg, South Carolina
Santee Hematology Oncology
Sumter, South Carolina
Seattle Cancer Care Alliance
Seattle, Washington
Centro de educacion medica c investigacioncs clinicas "Norberto Quimo' (CEMIC)
Buenos Aires, Argentina
Sanatorio Britanico S.A.
Santa Fe, Argentina
Royal North Shore Hospital, Haematology Department
New South Wales, Australia
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
St. Vincent's Hospital Sydney
Darlinghurst, New South Wales, Australia
Central Coast Local Health District
North Gosford, New South Wales, Australia
Calvary Mater Newcastle
Waratah, New South Wales, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Eastern Health - Box Hill Hospital
Box Hill, Victoria, Australia
St. Vincent's Hospital Melbourne
Fitzroy, Victoria, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
Border Medical Oncology
Wodonga, Victoria, Australia
Medical University of Innsbruck, University Clinic for Internal Medicine V
Innsbruck, Austria
Elisabeth Linz Hospital
Linz, Austria
Vienna Wilhelminen Hospital
Vienna, Austria
CHR de La Citadelle (ENG: Citadelle Regional Hospital Center)
Liège, Belgium
CHU Mont-Godinne
Yvoir, Belgium
ZNA, Stuivenberg
Antwerp, Antwerpen, Belgium
Saint Joseph Clinic Arlon, Department of Hematology
Arlon, Luxembourg, Belgium
University Multiprofile Hospital for Active Treatment "Sveti Georgi", Plovdiv, Hematology Clinic
Plovdiv, Bulgaria
University Multiprofile Hospital for Active Treatment "Sveti Georgi", Plovdiv, Oncology and Hematology Clinic
Plovdiv, Bulgaria
Military Medical Academy - Multiprofile Hospital for Active Treatment, Sofia, Hematology and Oncology Clinic
Sofia, Bulgaria
Specialized Hospital for Active Treatment of Hematological Diseases, Sofia, Hematology Clinic
Sofia, Bulgaria
Multiprofile Hospital for Active Treatment "Sveta Marina", Varna
Varna, Bulgaria
CSSS-Champlain-Charles LeMoyne
Greenfield Park, Quebec, Canada
307 Hospital of PLA
Beijing, China
Showing 40 of 213 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.